About SynDevRx

Intellectual Property

SynDevRx has developed proprietary technology that dramatically increases the activity of small molecule drugs while improving the safety profile and physical attributes.  This new class of drugs is based on our proprietary drug conjugation-release technology. 

Our IP is proprietary, and we are always expanding on it.

For more information or to inquire about licensing our technology, please contact us.

NB: SynDevRx is not affiliated with Children's Hospital Boston.